Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tebotelimab - MacroGenics

Next Previous
Drug Profile

Tebotelimab - MacroGenics

Alternative Names: Anti-LAG-3 bispecific DART protein; MGD-013; PD-1 x LAG-3 bispecific DART molecule; PD-1 X LAG-3 DART

Latest Information Update: 23 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; ZAI Lab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Gastric cancer; Oesophageal cancer
  • Phase II Head and neck cancer
  • Phase I Haematological malignancies; Solid tumours
  • Discontinued Biliary cancer; Cholangiocarcinoma; Endometrial cancer; Liver cancer; Malignant melanoma; Triple negative breast cancer

Most Recent Events

  • 23 Mar 2023 Tebotelimab is still in phase I trials for Haematological malignancies and Solid tumours in Australia, Bulgaria, Poland, Spain, Thailand, USA and Ukraine
  • 08 Feb 2023 MacroGenics completes a phase I trial for Solid tumors and Haematological malignancies (Combination therapy, Late stage disease, Metastatic disease, Inoperable/Unresectable) in USA, Australia, Bulgaria, Hong Kong, Poland, Spain, Thailand, Ukraine (IV) (NCT03219268)
  • 08 Feb 2023 MacroGenics completes a phase I trial for Solid tumors and Haematological malignancies (Monotherapy, Late stage disease, Metastatic disease, Inoperable/Unresectable) in USA, Australia, Bulgaria, Hong Kong, Poland, Spain, Thailand, Ukraine (IV) (NCT03219268)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top